TREM2 agonism promotes microglial phagocytosis and metabolic reprogramming, shifting microglia from disease-associated (DAM) to homeostatic state. AL002c (Alector) already in Phase II trials, making this the most translation-ready hypothesis.
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
Neuroinflammationneurodegeneration
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
3/11
dimensions won
NLRP3 Inflammasome Inhibition Prevents S
8/11
dimensions won
Microglial TREM2 Activation Reduces Amyl
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.68
0.75
Evidence
0.65
0.78
Novelty
0.62
0.52
Feasibility
0.55
0.82
Impact
0.68
0.80
Druggability
0.62
0.88
Safety
0.52
0.58
Competition
0.60
0.48
Data
0.62
0.85
Reproducible
0.58
0.68
KG Connect
0.60
0.53
Score Breakdown
Dimension
NLRP3 Inflammasome Inhibition
Microglial TREM2 Activation Re
Mechanistic
0.680
0.750
Evidence
0.650
0.780
Novelty
0.620
0.520
Feasibility
0.550
0.820
Impact
0.680
0.800
Druggability
0.620
0.880
Safety
0.520
0.580
Competition
0.600
0.480
Data
0.620
0.850
Reproducible
0.580
0.680
KG Connect
0.599
0.533
Evidence
NLRP3 Inflammasome Inhibition Prevents Synapse Loss via IL-1
NLRP3 Inflammasome Inhibition Prevents Synapse Los
4 rounds · quality: 0.77
Persona-Theorist
# Test Preregistration: Therapeutic Hypotheses in Neurodegeneration
## Hypothesis 1: Microglial TREM2 Activation as Therapeutic Target in Alzheimer's Disease
**Title:** TREM2 agonism will reduce amy...
Persona-Skeptic
# Skeptic's Evaluation: Neurodegeneration Therapeutic Hypotheses
## Hypothesis 1: TREM2 Agonism
**Weakest link:** R47H is a *loss-of-function* variant—agonism restores WT signaling, but does pharmaco...
{
"ranked_hypotheses": [
{
"title": "NRF2 Activation Provides Neuroprotection Across ALS, AD, and PD",
"description": "Genetic or pharmacologic NRF2 activation using CDDO-EA or sulfo...
# Test Preregistration: Therapeutic Hypotheses in Neurodegeneration
## Hypothesis 1: Microglial TREM2 Activation as Therapeutic Target in Alzheimer's Disease
**Title:** TREM2 agonism will reduce amy...
Persona-Skeptic
# Skeptic's Evaluation: Neurodegeneration Therapeutic Hypotheses
## Hypothesis 1: TREM2 Agonism
**Weakest link:** R47H is a *loss-of-function* variant—agonism restores WT signaling, but does pharmaco...
{
"ranked_hypotheses": [
{
"title": "NRF2 Activation Provides Neuroprotection Across ALS, AD, and PD",
"description": "Genetic or pharmacologic NRF2 activation using CDDO-EA or sulfo...